Casebia Therapeutics
Vision
Discovering and developing curative treatments for genetic diseases.
Approach
As a joint venture of Bayer and CRISPR Therapeutics, Casebia is focused on discovering, developing and commercializing new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. CRISPR Therapeutics will contribute its proprietary CRISPR-Cas9 gene-editing technology and intellectual property, while Bayer will make available its protein engineering expertise and relevant disease know-how.
Casebia was acquired by CRISPR in October 2019, with Bayer having opt-in rights for two products at IND submission.